Dynamic regulation of *Pdx1* enhancers by Foxa1 and Foxa2 is essential for pancreas development

Nan Gao,^{1,2} John LeLay,^{1,2} Marko Z. Vatamaniuk,^{1,2} Sebastian Rieck,^{1,2} Joshua R. Friedman,³ and Klaus H. Kaestner^{1,2,4}

¹Department of Genetics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; ²Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA;

³Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

The onset of pancreas development in the foregut endoderm is marked by activation of the homeobox gene *Pdx1* (*IPF1*). *Pdx1* is essential for the expansion of the pancreatic primordium and the development of endocrine islets. The control of *Pdx1* expression has been only partially elucidated. We demonstrate here that the winged-helix transcription factors Foxa1 and Foxa2 co-occupy multiple regulatory domains in the *Pdx1* gene. Compound conditional ablation of both *Foxa1* and *Foxa2* in the pancreatic primordium results in complete loss of *Pdx1* expression and severe pancreatic hypoplasia. Mutant mice exhibit hyperglycemia with severely disrupted acinar and islet development, and die shortly after birth. Assessment of developmental markers in the mutant pancreas revealed a failure in the expansion of the pancreatic anlage, a blockage of exocrine and endocrine cell differentiation, and an arrest at the primitive duct stage. Comparing their relative developmental activity, we find that Foxa2 is the major regulator in promoting pancreas development and cell differentiation. Using chromatin immunoprecipitations (ChIP) and ChIP sequencing (ChIPSeq) of fetal pancreas and islet chromatin, we demonstrate that Foxa1 and Foxa2 predominantly occupy a distal enhancer at -6.4 kb relative to the transcriptional start site in the *Pdx1* gene. In addition, occupancy of the well-characterized proximal *Pdx1* enhancer by Foxa1 and Foxa2 is developmental stage-dependent. Thus, the regulation of *Pdx1* expression by Foxa1 and Foxa2 is a key early event controlling the expansion and differentiation of the pancreatic primordia.

[**Keywords:** Pancreas; development; *Pdx1*; Foxa1; Foxa2; conditional gene ablation]

Supplemental material is available at <http://www.genesdev.org>.

Received June 27, 2008; revised version accepted October 17, 2008.

Mouse pancreas development begins on embryonic day 8.5–9.0 (E8.5–E9.0) when two epithelial buds emerge from the ventral and dorsal surfaces of the posterior foregut endoderm. These rudimentary buds undergo branching morphogenesis to form a ductal tree consisting primarily of undifferentiated ductal epithelia or pancreatic cords. By E13.5–E14.5, intensive epithelial cell proliferation and differentiation initiates in what has been termed the “secondary transition,” and by E16.5, exocrine acinar cells separate from the central ducts while endocrine cells begin to cluster into islet-like structures. Additional islet remodeling and maturation is completed 3 wk after birth, resulting in a mature functional pancreas (Jorgensen et al. 2007).

These early morphogenetic processes coincide with extensive migration and differentiation of epithelial cell

lineages, whose fate can be traced through the dynamic expression of several key transcription factors. For instance, the initial expression of *Pdx1* (E8.5–E9.0) highlights the prospective pancreatic domain even before the pancreatic buds can be distinguished morphologically. The initial broad expression of *Pdx1* becomes restricted to differentiated β - and δ -cells upon the completion of the secondary transition (Guz et al. 1995). Lineage tracing studies have shown that *Pdx1*Cre⁺ precursors give rise to all three epithelial cell lineages (ductal, exocrine, and endocrine) of the pancreas (Gu et al. 2003), consistent with the finding that *Pdx1* ablation causes pancreatic agenesis (Jonsson et al. 1994; Offield et al. 1996).

Like *Pdx1*, *Ptf1a*⁺ precursor cells contribute to all three cell lineages; however, its expression becomes restricted to acinar progenitor cells by E13.5 (Kawaguchi et al. 2002), consistent with the total absence of acinar cells in the *Ptf1a*-deficient pancreas (Krapp et al. 1998). In contrast, *Ngn3* specifically marks islet precursor cells

⁴Corresponding author.

E-MAIL kaestner@mail.med.upenn.edu; FAX (215) 573-5892.

Article is online at <http://www.genesdev.org/cgi/doi/10.1101/gad.1752608>.

(Apelqvist et al. 1999; Schwitzgebel et al. 2000; Gu et al. 2002), and the *Ngn3*-null pancreas does not develop endocrine cells (Gradwohl et al. 2000). Once committed to the endocrine fate, the final differentiation of individual hormone-producing cells (α , β , δ , ϵ , and PP cells) is dependent on a number of transcription factors, including members of the paired-box transcription factor family (*Pax*), the NK2 homeoprotein transcription factor (*Nkx*), the forkhead box transcription factors, and the Maf transcription factors (Lee et al. 2002, 2005; Habener et al. 2005; Vatamaniuk et al. 2006; Murtaugh 2007).

Although multiple DNA-binding proteins have been shown to participate in the elaboration of pancreatic cell types, the transcriptional events that govern the earliest steps in organ development remain to be fully elucidated. Recent studies have defined the *cis*-regulatory elements of *Pdx1* that are critical for the maintenance of precise *Pdx1* expression levels and thus for pancreas development (Fujitani et al. 2006). This essential enhancer of the *Pdx1* gene, termed "Area I–II–III," harbors binding sites for multiple *trans*-activators including *Foxa2* (Wu et al. 1997; Gerrish et al. 2000, 2001; Samaras et al. 2002, 2003; Fujitani et al. 2006; Wiebe et al. 2007; Vanhoose et al. 2008). Transgenic rescue further confirmed that this enhancer element is sufficient to direct *Pdx1* expression and restore pancreas development and islet maturation in *Pdx1*^{−/−} mice (Gannon et al. 2001; Boyer et al. 2006). In contrast to this principal control region located between −2800 and −1600 base pairs (bp), the contribution of a highly conserved distal enhancer element between −6530 and −6045 bp, termed "Area IV," is less clear (Gerrish et al. 2004). Independent of Area I–II–III, this distal enhancer is capable of directing pancreatic β -cell-selective reporter gene expression and potentiating the proximal enhancer activity (Sharma et al. 1997; Gerrish et al. 2004).

In vitro *Foxa2* binding to these *Pdx1* enhancers has been studied by several groups (Sharma et al. 1997; Wu et al. 1997; Gerrish et al. 2000, 2004; Ben-Shushan et al. 2001). To evaluate the importance of the suggested regulatory hierarchy between *Foxa2* and *Pdx1* in vivo, we previously used endoderm-specific or β -cell-specific *Foxa2* mutants (*Foxa2*^{loxP/loxP}, *Foxa3Cre*; *Foxa2*^{loxP/loxP}, *InsCre*) mice. *Foxa2* deficiency resulted in the absence of mature α cells and a reduction of *Pdx1* expression and β -cell differentiation (Lee et al. 2002, 2005). Given that *Foxa1* is a close homolog to *Foxa2* and contains an almost identical DNA-binding domain (Lai et al. 1991; Kaestner et al. 1994), we hypothesized that this factor may also participate in the regulation of *Pdx1*, and thus control pancreas development.

Here we report that, using a novel *Foxa1* loxP allele, removal of both *Foxa1* and *Foxa2* from the pancreatic primordia causes near total pancreatic agenesis and loss of *Pdx1* expression. Both *Foxa* factors predominantly occupy the distal *Pdx1* enhancer during pancreas development, with an increase in *Foxa2* binding to both enhancers during development. These data establish that *Foxa1* and *Foxa2* act upstream of *Pdx1* in the regulatory hierarchy governing pancreatic development.

Results

The Pdx1 enhancer is bound by both Foxa1 and Foxa2 in vivo

Foxa1 is coexpressed with *Foxa2* in the foregut endoderm from which the pancreatic buds are derived (Monaghan et al. 1993). Both genes are activated during early pancreas development, with highest levels in mature islets (Supplemental Fig. 1A). Given the high degree of sequence similarity between mouse *Foxa1* and *Foxa2*, especially in the DNA-binding domain (Lai et al. 1991; Kaestner et al. 1994), we hypothesized that *Foxa1* binds to the previously described *Foxa2* sites within the regulatory regions of the *Pdx1* gene (Area I–II–III; Supplemental Fig. 1B) (Wu et al. 1997; Gerrish et al. 2000; Ben-Shushan et al. 2001), and both factors participate in regulating *Pdx1* expression in the pancreatic anlage. We performed chromatin immunoprecipitation (ChIP) assays with antibodies specific to either *Foxa1* or *Foxa2* on chromatin isolated from primary mouse islets. Both *Foxa1* and *Foxa2* bound to the Area I–II–III enhancer of *Pdx1* in vivo (Supplemental Fig. 1C).

Derivation of Foxa1^{loxP} mice

Foxa1^{−/−} mice elaborate a morphologically normal pancreas, but exhibit reduced *Gcg* (*glucagon*) transcript levels and die shortly after birth (Kaestner et al. 1999; Shih et al. 1999). These *Foxa1*^{−/−} mice also have defects in β -cell function (Vatamaniuk et al. 2006) and in nonpancreatic tissues (Behr et al. 2004; Gao et al. 2005; Wan et al. 2005; Ferri et al. 2007). In order to study pancreas development without confounding effects from other tissues, we designed a novel loxP conditional allele for *Foxa1*. A targeting vector, engineered to flank exon 2 of *Foxa1* with a single loxP site and a *FRT-PGKneo-FRT-loxP* cassette (Supplemental Fig. 2A), was electroporated into embryonic stem (ES) cells. Correctly targeted ES clones were identified by Southern blot with a 5' external probe (Supplemental Fig. 2B) and expanded for blastocyst injection. One of the resulting chimeric males transmitted the loxP allele through the germ line. F1 offspring were bred to *Flp1* "deleter" mice (Rodriguez et al. 2000), which express the Flp recombinase enzyme ubiquitously, for removal of the FRT-flanked PGKneo cassette (Supplemental Fig. 2A). *Foxa1*^{loxP/loxP} mice (Supplemental Fig. 2C), obtained by intercrossing of *Foxa1*^{loxP/+} mice, were healthy and fertile, confirming that the *Foxa1*^{loxP} allele is functionally wild type. The subsequent Cre-mediated excision of the loxP-flanked target resulted in a *Foxa1*-null allele that lacks the coding sequence for the entire DNA-binding domain.

Severe pancreatic hypoplasia in compound Foxa1 and Foxa2 mutants

To investigate whether *Foxa1* and *Foxa2* cooperate in early pancreas development, we derived *Foxa1*^{loxP/loxP}, *Foxa2*^{loxP/loxP}, *Pdx1Cre*^E mice using the *Foxa1*^{loxP} allele

described above and the previously reported *Foxa2*^{loxP} (Sund et al. 2000) and *Pdx1Cre*^{Early} mice (referred to as *Pdx1Cre*^E throughout) (Gu et al. 2002; Heiser et al. 2006). Surprisingly, *Foxa1*^{loxP/loxP}, *Pdx1Cre*^E mice (*n* = 20) and *Foxa1*^{loxP/loxP}, *Foxa2*^{loxP/+}, *Pdx1Cre*^E mice (*n* = 61) were not only viable and fertile, but also euglycemic (Supplemental Fig. 2D). Given that the *Pdx1Cre*^E transgene mediates gene ablation in the entire endocrine pancreas including α cells (Gu et al. 2002), this finding demonstrates that the neonatal lethality of *Foxa1*^{-/-} mice is the consequence of nonpancreatic defects (Kaestner et al. 1999; Behr et al. 2004). In contrast, *Foxa1*^{loxP/loxP}, *Foxa2*^{loxP/loxP}, *Pdx1Cre*^E mice (*n* = 37) were severely hyperglycemic (Supplemental Fig. 2D) and died within the first 2 d of life. Interestingly, *Foxa1*^{loxP/+}, *Foxa2*^{loxP/loxP}, *Pdx1Cre*^E mice (*n* = 8) also died before postnatal day 5.

In *Foxa1*^{loxP/loxP}, *Foxa2*^{loxP/loxP}, *Pdx1Cre*^E mice (referred to as “compound mutants” below), Cre recombinase initiated deletion of both genes on E9.0. When we analyzed embryos at late gestation (E18.5), only minimal pancreatic tissue remained in the compound mutant mice, in contrast to their control littermates (Fig. 1A–D). This dramatic phenotype exhibited variable penetrance

in mutant mice, affecting either the ventral or dorsal pancreas (Fig. 1B,C), or both (Fig. 1D). This severe pancreatic hypoplasia explains the early postnatal death of *Foxa1/Foxa2* compound mutant mice. As expected, no Foxa1 or Foxa2 protein was detected by immunohistochemistry in the remaining pancreatic tissue recovered from compound mutants at E18.5 (Fig. 1E,G), while a concomitant loss of Pdx1 protein in these mutant tissues was revealed in adjacent sections (Fig. 1F,H). In contrast to the pancreas, the duodenum developed normally in compound mutants. Equivalent levels of Foxa1/Foxa2 proteins were detected by immunohistochemistry in control and mutant duodenal epithelia using an antibody that recognizes both Foxa1 and Foxa2, and the distribution of Foxa1/Foxa2⁺ cells within the duodenal epithelia was also identical (Fig. 1I,J). Because *Pdx1Cre*^E expression in the duodenum is mosaic, this is either because the transgene did not result in *Foxa1/Foxa2* deletion in this tissue or because *Foxa1/Foxa2*-null cells were replaced by wild-type cells.

Decreased Pdx1 in the pancreatic buds of Foxa1/Foxa2 compound mutants

Even though Pdx1 is a master regulator of pancreas formation, and *Pdx1* mutant mice or people lack a mature pancreas (Jonsson et al. 1994; Stoffers et al. 1997), pancreas development is initiated in *Pdx1*^{-/-} mice, and a small pancreatic rudiment is present (Offield et al. 1996). We examined pancreatic bud formation in *Foxa1/Foxa2* compound mutant animals utilizing the *Rosa26R* reporter line, which marks those cells in which the *Pdx1Cre*^E has been active. Both dorsal and ventral pancreatic buds formed (Fig. 2A–D, E9.5) and initially expanded (Fig. 2E–H, E10.5) in compound mutant mice. Sections of these β -gal-stained embryos were analyzed by immunohistochemistry for Foxa1/2. In contrast to control pancreatic buds (Fig. 2I), where nuclear Foxa1/Foxa2 was detected in both the foregut epithelium and the growing tips of the pancreatic primordia at E9.5 (Fig. 2I,K), a vast majority of the cells in the compound mutant pancreas were Foxa1/Foxa2-negative (Fig. 2J,L), except for a few scattered cells in the pancreatic anlage that retained nuclear staining (Fig. 2L, arrow). The gut epithelium of the mutant embryos was clearly Foxa1/Foxa2-positive (Fig. 2J).

Pdx1 expression was reduced in compound mutant pancreatic anlagen compared with control sections as early as E9.5 (Supplemental Fig. 3A,B). At E10.5, the growing pancreatic epithelial buds in control mice strongly expressed Pdx1 (Fig. 2M–P), while Pdx1 expression in the mutant epithelial cords was almost completely extinguished (Fig. 2Q–T). Thus, early pancreatic primordia in compound mutant mice formed with a normal number of Pdx1⁺ precursor cells in which *Foxa1* and *Foxa2* had not yet been deleted, but by E10.5 the *Pdx1Cre*^E transgene efficiently removed both *Foxa* genes, resulting in a loss of Pdx1 expression in the developing pancreas.

Figure 1. Conditional ablation of *Foxa1* and *Foxa2* in the pancreatic primordia causes pancreatic hypoplasia. (A) Control E18.5 pancreas, outlined by the dotted line, is located between the stomach and duodenum. (B–D) *Foxa1* and *Foxa2* compound mutant pancreata were severely hypoplastic, with variable penetrance of the affected pancreatic lobes. Asterisks indicate the complete absence of the ventral pancreas. (E–H) Adjacent sections of control and compound mutant pancreas (E18.5) were stained for Foxa1/2 and Pdx1, with all three proteins being absent in the mutant pancreas. (I,J) Foxa1/Foxa2 expression in duodenal epithelia of the compound mutants was unaffected.

Figure 2. Loss of *Pdx1* expression in the pancreatic buds of compound mutant mice. (A–D) The pancreatic domain marked by the *Pdx1Cre^E* transgene was detected by β -galactosidase staining after introgression of the *Rosa26R* reporter allele into our *Foxa1^{loxP/loxP};Foxa2^{loxP/loxP};Pdx1Cre^E* mice. Both ventral and dorsal pancreatic buds (blue staining, arrows) were visible in compound mutant mice at E9.5. (E–H) These mutant buds expanded initially at E10.5. (I) As the pancreatic buds evaginated from the gut epithelium, *Foxa1/2* expression was seen in a majority of control pancreatic precursor cells as well as in the gut epithelium. The arrow points to the pancreatic bud, which is positive for nuclear *Foxa1/2*. (J) *Foxa1/2* expression was decreased in the pancreatic anlage of compound mutant mice at E9.5. (K) Higher magnification of I. (L) In compound mutant pancreatic buds, only scattered single cells remained *Foxa1/2*-positive (arrow). (M–T) Confocal fluorescent staining demonstrates that *Pdx1* expression is extinguished in the compound mutant pancreatic anlage on day E10.5. Control pancreatic epithelial cells strongly express *Pdx1*. E-cadherin staining indicates the extent of the pancreatic epithelium. Bars, 25 μ m.

Pancreatic precursor cells fail to expand in Foxa1/Foxa2-deficient buds

During early pancreas development, *Pdx1*-expressing precursor cells expand to form a branched system of epithelial cords. Outgrowth and differentiation of exocrine and endocrine progenitors from these primitive cords initiates around E13.5. We observed near normal amounts of pancreas tissue, as indicated by β -gal activity, in *Foxa1^{loxP/+};Foxa2^{loxP/+};Pdx1Cre^E;Rosa26R* mice at E13.5 (Fig. 3A,B). Interestingly, mice with only one remaining wild-type *Foxa2* allele (*Foxa1^{loxP/loxP};Foxa2^{loxP/+};Pdx1Cre^E*) developed normal dorsal and ventral pancreata (Fig. 3C,D). In contrast, the pancreas anlage of compound mutant mice failed to expand (Fig. 3E,F).

At E13.5, the control pancreas formed a ductal tree (Fig. 3G) concomitant with epithelial cell differentiation and proliferation. In contrast, the compound mutant pancreas contained epithelial cords without clear exocrine structure (Fig. 3H). This lack of morphological

transformation in mutant tissue was supported by the scarcity of immature endocrine and exocrine cells marked by glucagon (Fig. 3J) and amylase (Fig. 3L) antibodies, while an abundance of glucagon⁺ and amylase⁺ cells were detected in the control pancreas (Fig. 3I,K). In addition, *Cpa1*⁺ cells, which form the multipotent progenitor domains at the tips of the ductal tree at this stage (Fig. 3M; Zhou et al. 2007), were very rare in the compound mutant pancreas (Fig. 3N).

Using antibodies against *Ngn3* and *Ptf1a*, known lineage determinants for endocrine and exocrine cells, respectively, we observed abundant *Ngn3*⁺ cells in the control ductal trunk (Fig. 3O), and *Ptf1a*⁺ cells in emerging acini (Fig. 3Q). In sharp contrast, compound mutant pancreata contained only a few cells expressing either factor (Fig. 3P,R). To quantify this reduction, we counted *Ngn3*⁺ and *Ptf1a*⁺ cells that were colabeled by β -gal staining in the control and mutant pancreas (Supplemental Fig. 3). This analysis revealed an 84% and 93% reduction of *Ngn3*⁺ and *Ptf1a*⁺ cells, respectively, in compound mutants (Supplemental Fig. 3M). Thus, the compound

Figure 3. Pancreatic precursors fail to expand in *Foxa1* and *Foxa2* compound mutants. (A–F) Whole-mount gut tissues were dissected from E13.5 embryos of the indicated genotypes. Dorsal and ventral pancreata developed in *Foxa2*^{loxP/+}, *Foxa2*^{loxP/+}, *Pdx1*^{Cre^E} and *Foxa2*^{loxP/loxP}, *Foxa2*^{loxP/+}, *Pdx1*^{Cre^E} mice as indicated by β-galactosidase activity, but failed to grow in compound mutant mice (dotted lines). (G,H) E13.5 control pancreas formed a ductal epithelial tree with abundant exocrine structures visible at the ductal tips. Compound mutant pancreata consisted primarily of ducts. (I–R) Control and compound mutant sections were stained with glucagon (I,J), amylase (K,L), CPA1 (M,N), Ngn3 (O,P), and Ptf1a (Q,R) antibodies in red, and counterstained for E-cadherin (blue) or DNA (green). Bars, 25 μm.

mutant pancreatic epithelial cords failed to elaborate sufficient numbers of endocrine and exocrine progenitors, resulting in severely reduced numbers of glucagon⁺ and amylase⁺ cells.

Foxa1 and *Foxa2* are not equivalent in promoting pancreas development

In order to determine whether *Foxa1* and *Foxa2* are completely interchangeable in pancreas formation, we analyzed E14.5 mouse embryos with various combinations of *Foxa1* and *Foxa2* alleles. Interestingly, when one or both *Foxa2* wild-type alleles were present (Fig. 4A,B), the number of wild-type *Foxa1* alleles did not have an impact on pancreatic size. In other words, one copy of the *Foxa2* gene was sufficient to induce pancreas formation. When both *Foxa2* alleles were removed, however, a clear reduction in pancreatic mass was seen (Fig. 4C–F). Importantly, in this scenario, *Foxa1* gene copy number

became a determinant of the size of pancreatic lobes (Fig. 4, cf. C and E, and D and F). This was reflected by the relative area of the pancreas: 31% of control in *Foxa1*^{loxP/+}, *Foxa2*^{loxP/loxP}, *Pdx1*^{Cre^E} mice, compared with 19% in compound mutant mice (Fig. 4G). While these data demonstrate that *Foxa2* is more potent in promoting pancreas growth than *Foxa1*, *Foxa1* is also a positive regulator of pancreas development. In addition, although both pancreatic lobes were affected in these mutant mice, the ventral pancreas was more sensitive to *Foxa* deficiency than the dorsal pancreas (Fig. 4D,F).

The notion of differential competency of the two *Foxa* genes was supported by our analysis of late gestation pancreata. E17.5 mice with only one remaining wild-type *Foxa2* allele (*Foxa1*^{loxP/loxP}, *Foxa2*^{loxP/+}, *Pdx1*^{Cre^E}) specified similar numbers of exocrine and endocrine cells as control pancreata (Fig. 5A,B). In contrast, a dramatic reduction in both cell types was seen in the *Foxa1*^{loxP/+}, *Foxa2*^{loxP/loxP}, *Pdx1*^{Cre^E} pancreas (Fig. 5C).

Figure 4. Foxa1 and Foxa2 regulate pancreas growth with different potency. (A–F) Pancreas development in E14.5 mice with various combinations of *Foxa1* and *Foxa2* alleles, in mice with introgressed *Rosa26R* reporter allele. (A,B) One wild-type *Foxa2* allele is sufficient to specify a nearly normal-size pancreas. Severe hypoplasia was seen in *Foxa2^{loxP/+}, Foxa2^{loxP/loxP}, Pdx1Cre^E* mice (C,D) and compound mutants (E,F), with the ventral pancreas being affected more severely (D,F). (G) The extent of the pancreas, as marked by β -galactosidase activity of the *Rosa26R* reporter present in all embryos, was quantified in mice with indicated *Foxa1/Foxa2* genotypes.

However, when compared with the *Foxa1/Foxa2*-devoid pancreas, where amylase⁺ or glucagon⁺ cells were rarely seen (Fig. 5D), one copy of *Foxa1* was sufficient to specify a limited number of either cell type (Fig. 5C). Interestingly, while amylase⁺ and glucagon⁺ cells were clearly separated from each other in control pancreata, with amylase⁺ cells spread peripherally and glucagon⁺ cells occupying the central core (Fig. 5E,F), in *Foxa1^{loxP/+}, Foxa2^{loxP/loxP}, Pdx1Cre^E* and compound mutants, some double-positive (amylase⁺/glucagon⁺) cells were observed (Fig. 5G,H; Supplemental Fig. 4).

Likewise, one copy of *Foxa2* was sufficient to specify a nearly normal complement of insulin⁺ β cells as compared with control mice (Fig. 5I,J). In contrast, the number of β cells was greatly reduced in *Foxa1^{loxP/+}, Foxa2^{loxP/loxP}, Pdx1Cre^E* mice (Fig. 5K,O). Very few β cells were present in compound *Foxa1/Foxa2* mutant pancreata from E17.5 (Fig. 5L, arrow) through postnatal day 1 (data not shown). Accompanying the reduced endocrine cell mass, we noted a loss of total epithelial tissue in compound mutant pancreata (Fig. 5O,P), as indicated by E-cadherin staining (Fig. 5M–P). In fact, the remaining epithelial cells in the compound mutant pancreas were almost exclusively ductal, as they were strongly positive for DBA lectin (Fig. 5R). We detected only scattered single δ cells and ϵ cells in sections of compound mutant pancreas, demonstrating that α and β cells had not been reallocated to other lineages in *Foxa1/Foxa2*-deficient pancreas (data not shown). Finally, we found that the spaces between the remaining ductal epithelia in the compound mutant pancreas were filled with stromal tissue, including fibroblasts and smooth muscle cells, as identified by vimentin (Fig. 5S,T) and smooth muscle actin (data not shown) staining. Thus, compound loss of *Foxa1* and *Foxa2* arrested pancreas growth at the early pancreatic cord stage.

Foxa1/Foxa2 are required for the expression of several endocrine transcriptional regulators

Disrupting either *Nkx6.1* or *Nkx2.2* affects β -cell development (Sussel et al. 1998; Sander et al. 2000; Wang et al. 2004), while abolishing *Pax6* primarily inhibits α -cell differentiation (Sander et al. 1997). None of these mutants demonstrates a phenotype with a severity comparable with that of *Pdx1*-null (Jonsson et al. 1994; Offield et al. 1996), or *Foxa1/2* compound mutant pancreata. We examined the impact of *Foxa1* and *Foxa2* compound mutation on several early transcription factors shown to be critical for islet development. Although these key regulators were present in control endocrine compartments with expression patterns consistent with the literature (Fig. 6A–D,I–L), they were largely depleted in the *Foxa1/Foxa2* compound mutant pancreas (Fig. 6E–H, M–P). This was illustrated by costaining for these factors with *Foxa1/2*, which were expressed in all control pancreatic epithelial cells (Fig. 6A,K) but only in scattered compound mutant cells (Fig. 6E,O, arrows). These single *Foxa1/2*-positive cells had apparently escaped Cre-mediated gene excision, and coexpressed *Nkx6.1* (Fig. 6F), *Pdx1* (Fig. 6G), *Pax6* (Fig. 6M), and *Nkx2.2* (Fig. 6N). In addition, we analyzed the expression of *Isl1*, which has been shown to be essential for formation of the dorsal pancreas (Ahlgren et al. 1997). In contrast to controls (Fig. 6Q,R), we found a dramatic reduction in the number of *Isl1*-expressing cells in compound mutant tissues (Fig. 6S,T), where the majority of the remaining *Isl1*-positive cells coexpressed *Foxa1/2* protein in their nuclei. Thus, disruption of *Foxa1* and *Foxa2* caused pancreatic tissue loss with a concomitant reduction of cells expressing key transcriptional regulators.

Figure 5. Disrupted pancreatic differentiation in compound mutants. (A–R) Indirect immunofluorescent staining of E17.5 pancreas sections from mice with the indicated genotypes for amylase and glucagon (A–H), insulin (I–L), E-cadherin and insulin (M–P), DBA and insulin (Q–R), or vimentin (S–T) antibodies and visualized by confocal microscopy. Arrows in G and H point to apparently double-positive amylase⁺/glucagon⁺ cells, and the optical section depth in these micrographs is 0.7 μ m. Arrow in L points to a single insulin⁺ cell in the compound mutant pancreas. Bars: A–D, 100 μ m; E–H, 17.5 μ m; I–T, 50 μ m.

Foxa occupancy of the distal and proximal Pdx1 enhancers

Both Foxa1 and Foxa2 bind to the proximal enhancer Area I–II–III, in the *Pdx1* gene in mature pancreatic islets (Supplemental Fig. 1). When Area I–II–III is deleted by gene targeting, the resulting mice display severe pancreatic hypoplasia; however, they develop a larger pancreas than our Foxa1/Foxa2 compound mutants, with ample exocrine tissue and even some endocrine cells remaining (Fujitani et al. 2006). Combined with our finding that Foxa1/Foxa2-deficient cells extinguish *Pdx1* expression completely, we hypothesized that Foxa1 and Foxa2 may bind to additional enhancer elements in the regulatory regions of *Pdx1* that were not deleted by Fujitani et al. (2006). To address this question, we performed ChIP sequencing (ChIPSeq) experiments using a Foxa2-specific antibody on chromatin isolated from E14.5 wild-type fetal pancreas and primary islets, respectively. We chose E14.5 pancreas, since at this stage all acinar cells con-

tinue to express Pdx1, and Pdx1-expressing progenitor cells are still present in large numbers in the central epithelial cords. Alignment of the sequence tags obtained to the *Pdx1* locus revealed that in the fetal pancreas, Foxa2 does not bind effectively to the well-characterized Area I–II–III enhancer, but rather predominantly to Area IV farther upstream (Fig. 7A,B). This enhancer element, located 6.4 kb upstream of the transcription start site, is highly conserved among different animal species (Fig. 7B; Gerrish et al. 2004). Notably, the binding of Foxa2 to Area IV or Area I–II–III is significantly enhanced in pancreatic islets compared with fetal pancreas (Fig. 7B).

Real-time PCR with primers specific for Area IV confirmed our ChIPSeq data, demonstrating an average enrichment of 13-fold and 56-fold in Foxa2 immunoprecipitated DNA compared with input DNA in E14.5 pancreas and adult pancreatic islets, respectively (Fig. 7C). In contrast, the average ChIP enrichments for Area I–II were only 2.3-fold and 6.4-fold in E14.5 pancreas and

Figure 6. The impact of Foxa1 and Foxa2 ablation on the pancreatic transcription factor network. E18.5 pancreas sections from control and compound mutant mice were stained with Foxa1/2, Nkx6.1, and Pdx1 (A–H); Pax6, Nkx2.2, and Foxa1/2 (I–P); or Isl1 and Foxa1/2 (Q–T) antibodies by indirect immunofluorescence and visualized by confocal microscopy. Arrows, in compound mutant sections, point to remaining Foxa1/2-positive cells that coexpress additional pancreatic transcription factors. Asterisks in G, H, R, and S mark the ducts. H, P, and Q–T are bright-field images or merged images including bright-field images. Bars: R, T, 17.5 μ m; all others, 30 μ m.

islet, respectively (Fig. 7C). Foxa2 ChIP of pancreatic chromatin samples from various developmental stages demonstrated that Foxa2 occupancy of Area I–II increases with age (Fig. 7C). Although the binding of Foxa2 to Area IV is always greater than to Area I–II (Fig. 7C), it is important to note that the Foxa2 ChIP enrichment for Area I–II is statistically significant compared with input throughout all fetal stages tested ($P < 0.05$).

ChIP assay using a Foxa1-specific antibody revealed that the binding affinity of this protein for Area IV is also greater than that for Area I–II, with maximal occupancy in mature islets (Fig. 7C). In contrast, Foxa1 shows near constant binding to Area I–II throughout pancreas development (Fig. 7C). An overall lower ChIP enrichment was seen from Foxa1ChIP experiment compared with Foxa2 ChIP, which could either reflect the relative abundance or intrinsic affinity of the two proteins, or differences in the efficacy of the two antibodies used. Thus, while we are able to analyze the developmental time course of enhancer occupancy for each factor individually during

pancreatic development, we cannot assess which of the two proteins occupies more binding sites in vivo.

The strong binding of both Foxa1 and Foxa2 to the Area IV enhancer in early pancreas development supports the observation that this enhancer alone is capable of directing *Pdx1* expression (Sharma et al. 1997; Gerrish et al. 2004). This finding also explains why the phenotype of the Area I–II–III enhancer mutant described by Fujitani et al. (2006) is milder than the one we describe in our compound mutants. Our data demonstrate that differential occupancy of various *cis*-regulatory elements in the *Pdx1* gene by Foxa1 and Foxa2 is dependent on developmental time, adding a further dimension to the regulatory properties of these transcription factors.

Discussion

Signals from the adjacent mesoderm initiate pancreas formation (Moriya et al. 2000; Stafford and Prince 2002; Chen et al. 2004; Martin et al. 2005; Molotkov et al.

pound mutant mice and transiently expressed Pdx1. During the primary transition these precursor cells gave rise to daughter cells in the primitive pancreatic ducts. The remaining Pdx1 protein in these early ductal epithelia likely reflects the time required for the deletion of the four *Foxa1/2* gene alleles, the degradation of Foxa1/2 proteins carried over from the endoderm parental cells, the loss of *Pdx1* gene transcription, and the decay of existing Pdx1 protein. Thus, the variable penetrance of the mutant phenotype described above may reflect slight variations in the timing of *Foxa1/Foxa2* deletion. Nevertheless, *Pdx1* expression in exocrine and endocrine cells, as well as the differentiation of these tissues from the ductal epithelia, was completely dependent on *Foxa1* and *Foxa2*. This conclusion is supported by the overall disruption of acinar and endocrine differentiation in *Foxa1/Foxa2* compound mutant mice. The immediate consequences of this disrupted differentiation program are the severely reduced exocrine and endocrine progenitor cell populations (Ngn3⁺ and Ptf1⁺ cells), which determine the ultimate pancreatic mass. The attenuation of the multipotent progenitor domain was pronounced, consis-

tent with the drastically reduced ductal tip outgrowth and differentiation in the mutant pancreas. Our results are summarized schematically in Figure 8. The near total absence of β cells and other mature exocrine and endocrine cell types (Fig. 8A) represents the cumulative blockage of pancreatic differentiation at multiple transitional steps where Foxa1 and Foxa2 are needed (Fig. 8B). These changes are consistent with the decrease in cells expressing various endocrine transcriptional regulators. Further, the expression of these factors, including Nkx6.1, Nkx2.2, Pax6, Isl1, and Pdx1, in the few cells that retained Foxa1/2 in the mutant pancreas is consistent with a cell-autonomous regulatory effect of the Foxa factors in pancreas differentiation.

Developmental occupancy of Pdx1 enhancers

Foxa1/Foxa2 compound mutants display a more severe phenotype in exocrine pancreas development than $Pdx1^{\Delta I-II-III/\Delta I-II-III}$ mice, as acinar cells are abundantly

present the latter model (Fujitani et al. 2006). This discrepancy is explained by our discovery that throughout early pancreas development, Foxa1 and Foxa2 predominantly bind to Area IV, a region left intact in the $Pdx1^{\Delta I-II-III/\Delta I-II-III}$ model. Previous experiments have shown that key pancreatic transcription factors, including Foxa2, Pdx1, and Nkx2.2 are capable of transactivating this enhancer region in vitro (Gerrish et al. 2004). Furthermore, this distal enhancer can independently direct Pdx1 expression and potentiate proximal enhancer activity (Sharma et al. 1997; Gerrish et al. 2004). Thus, in the absence of Area I–II–III, Area IV plus Foxa1/Foxa2 are sufficient to specify some acinar development, while endocrine differentiation is blocked (Fig. 8C; Fujitani et al. 2006).

Although Foxa1 and Foxa2 bind to Area I–II–III with relatively low affinity, both factors occupy this core enhancer element throughout pancreas development and in mature islets. Our data support the importance of Foxa1/Foxa2 occupancy of the Area I–II–III enhancer, as

Figure 8. Occupancy of two *Pdx1* enhancers by Foxa1 and Foxa2 controls pancreas development. (A) Loss of Foxa1 and Foxa2 prevents the expansion and differentiation of pancreatic progenitor cells, leading to disrupted exocrine and endocrine development. (B) Foxa1 and Foxa2 are among the earliest factors required for the expansion of pancreatic progenitors, the differentiation of endocrine and exocrine compartments, and the maturation of islet cells. (C) Diagram illustrating the *cis*-regulatory elements of *Pdx1*, including the distal enhancer (Area IV; red box), and the proximal enhancer (Area I–II–III; green boxes). (a) In the wild-type embryo, both enhancers, together with key transactivators including Foxa1/Foxa2 (yellow diamonds) direct *Pdx1* gene (blue box) expression and normal pancreas development. (b) Ablation of *Pdx1* causes abrogation of pancreas development, with only a small dorsal ductule remaining (Jonsson et al. 1994; Offield et al. 1996). (c) A *Pdx1* transgene directed by either a 6.2-kb fragment including Area I–II–III and half of Area IV, or a 4.5-kb fragment including only Area I–II–III is capable of rescuing the *Pdx1*^{−/−} pancreas phenotype (Gannon et al. 2001; Boyer et al. 2006). (d) Targeted deletion of Area I–II–III leads to severe pancreatic hypoplasia, affecting in particular the endocrine compartment, while acinar tissue does form (Fujitani et al. 2006). (e) Removal of Foxa1 and Foxa2 in the early pancreatic buds, as shown in this study, causes elimination of *Pdx1* expression and disrupted exocrine and endocrine pancreas development.

previously demonstrated by in vitro experiments (Gerish et al. 2000). The transactivation of Area I–II–III by Foxa1/Foxa2 and other factors such as Ptf1a (Wiebe et al. 2007) is sufficient for some level of *Pdx1* expression, since a *Pdx1* transgene driven by Area I–II–III alone rescued the *Pdx1*^{−/−} pancreas phenotype (Fig. 8C; Boyer et al. 2006). Our data and previous work (Fujitani et al. 2006) further suggest that endocrine differentiation requires higher levels of *Pdx1* expression than acinar development.

Differential contributions of Foxa factors to pancreas development

Our study, utilizing a novel *Foxa1* conditional allele, overcomes a major drawback of experiments using *Foxa1*^{−/−} mice that, in addition to endoderm defects, have neurological and renal phenotypes as well (Behr et al. 2004; Ferri et al. 2007). Unexpectedly, *Foxa1*^{loxP/loxP}, *Pdx1Cre*^E mice did not demonstrate major defects in pancreas development. Most strikingly, *Foxa1*^{loxP/loxP}, *Foxa2*^{loxP/+}, *Pdx1Cre*^E mice, with only one copy of wild-type *Foxa2*, developed a relatively normal pancreas with all mature cell types, and were metabolically healthy. In contrast, mice with one allele of wild-type *Foxa1* alone failed to thrive. Thus, one allele of *Foxa2*, but not *Foxa1*, was sufficient for normal pancreas development and function, suggesting that the previously reported postnatal death of *Foxa1*^{−/−} mice (Kaestner et al. 1999; Shih et al. 1999) is due to nonpancreatic defects.

The notion that Foxa1 is a positive regulator of pancreas development is supported by the findings that (1) in the absence of both *Foxa1* and *Foxa2* genes, very few amylase⁺ or glucagon⁺ cells, and no β cells were specified; (2) in the absence of *Foxa2*, one allele of *Foxa1* specified more amylase⁺, glucagon⁺, and β cells than no *Foxa1* alleles; and (3) in the absence of *Foxa2*, two alleles of *Foxa1* specified a pancreas with exocrine and endocrine compartments, albeit with reduced α -cell number (Lee et al. 2005).

We were also able to directly compare the “developmental potency” of Foxa1 and Foxa2 in vivo. While both Foxa proteins can occupy the *Pdx1* enhancers, binding by Foxa2 appears to predominate, if one assumes that the efficacy of ChIP with both antibodies is equivalent. This relative comparison to a large extent agrees with our in vivo data as well as previous observations that two copies of the *Foxa1* (as in *Foxa2*^{loxP/loxP}, *Foxa3Cre* mice) (Lee et al. 2005) promote pancreatic development with fewer α cells than one copy of the *Foxa2* gene alone (in *Foxa1*^{loxP/loxP}, *Foxa2*^{loxP/+}, *Pdx1Cre*^E mice). We conclude that the dynamic regulation of *Pdx1* enhancers by Foxa2 and Foxa1 plays a critical role in pancreas development.

Materials and methods

Mice

The *Foxa1* loxP targeting vector was constructed by retrieval of a 7.9-kb genomic DNA sequence encompassing the *Foxa1* gene

from a bacterial artificial chromosome (University of California at Santa Cruz), followed by insertion of a loxP sequence 273 bp upstream, and a FRT-PGKneo-FRT-loxP fragment immediately downstream from exon 2. Homologous recombination in the R1 ES cell line was screened by Southern blot with a 5′-external probe. Wild-type and targeted alleles were identified as 7.4-kb HindIII and 4.0-kb HindIII/SpeI fragments, respectively. Targeted ES cells were injected into C57/BL6 blastocysts, and one of the resulting chimeric males transmitted the loxP allele through the germ line. The offspring were bred to Flp1 deleter mice (Rodriguez et al. 2000) for removal of the FRT-flanked PGKneo cassette, resulting in *Foxa1*^{loxP/+} mice identified by genomic PCR with the following primers: forward, 5′-CTGTG GATTATGTTCTCTGAT-3′; and reverse, 5′-GTGTCAGGATG CCTATCTGGT-3′. *Foxa2*^{loxP/+} (Sund et al. 2001), *Pdx1Cre*^E (Gu et al. 2002; Heiser et al. 2006), and *Rosa26R* (Soriano 1999) mice have been described previously. Blood glucose levels were measured as previously described (Gao et al. 2007).

β -galactosidase staining and immunohistochemistry

Embryos or whole-mount pancreata were dissected into fresh PBS, fixed for 1 h in PBS with 1% formaldehyde, 0.2% glutaraldehyde, 2 mM MgCl₂, 5 mM EGTA, 0.2% NP-40, and washed in PBS with 0.2% NP-40 three times. Embryos or tissues were then stained overnight at 37°C in a solution containing 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 2 mM MgCl, 0.01% sodium deoxycholate, 0.02% NP-40, and 1 mg/mL X-gal. Embryos were washed three times in PBS with 0.02% NP-40 and post-fixed in 4% paraformaldehyde. Whole embryos or tissues were imaged using a Leica dissecting microscope. To quantify the pancreatic tissue, one representative image was taken for each β -galactosidase-stained whole-mount tissue, and two-dimensional areas of β -galactosidase-positive pancreases were measured by ImageJ 1.38x (National Institutes of Health).

For immunohistochemistry after β -galactosidase staining, embryos or tissues were incubated in 30% sucrose in PBS overnight, embedded in OCT, and cryosectioned. Immunohistochemistry was performed using the Vectastain Elite ABC kit (Vector Laboratories). Primary antibodies used in immunohistochemistry included mouse anti-Ngn3 (1:1000; Developmental Studies Hybridoma Bank at the University of Iowa, F25A1B3), rabbit anti-Ptf1a (1:5000; gift from C. Wright, Vanderbilt University), guinea pig anti-Pdx1 (1:1000; gift from C. Wright), goat anti-Foxa1/2 (1:1000; Santa Cruz Biotechnologies, sc-6553), rabbit anti-carboxypeptidase A (1:1500; AbD Serotec, 1810-0006), rabbit anti-glucagon (predilute; Invitrogen, 080064), and rabbit anti-amylase (1:1000; Sigma, A8273). For quantification, Ngn3⁺ or Ptf1a⁺ cells from one section of each five control and five compound mutant embryos were manually counted under a light microscope.

Immunofluorescent analysis

Procedures of confocal immunofluorescent analysis have been described previously (Gao et al. 2007). Primary antibodies not mentioned above included guinea pig anti-insulin (1:1000; Linco), mouse anti-E-cadherin (1:500; BD Biosciences), biotinylated dolichos biflorus agglutinin (1:1000; Vector Laboratories), rabbit anti-Pax6 (1:500; Covance, PRB-278P), mouse anti-Nkx2.2 (1:50; Developmental Studies Hybridoma Bank), mouse anti-Nkx6.1 (1:500; Developmental Studies Hybridoma Bank), and mouse anti-Isl1 (1:50; Developmental Studies Hybridoma Bank).

ChIP

Foxa1 and Foxa2 ChIP were performed as described (Friedman et al. 2004), using antibodies against Foxa1 (Santa Cruz Biotechnologies, sc-22841) and Foxa2 (Santa Cruz Biotechnologies, sc-6554), or Foxa1-specific antiserum (kind gift of G. Schütz, Heidelberg, Germany), and Foxa2-specific antiserum (kind gift of J.A. Whitsett). The ChIP PCR primers spanned the Foxa2-binding sites within Area I-II and IV of the mouse *Pdx1* 5' upstream sequence (Wu et al. 1997; Gerrish et al. 2000, 2004) Area1F, TGCCTGCAAAACCACTAAGA; Area1R, GAGGTACCCTGCCTCCTCTC; Area2F, ATGAAGCGTCGAGATGGAAG; Area2R, CACCCCAGGATGTTTGCTTA; Area 4F, TGCCTCAGTGCCTTTACTC; Area4R, CTAAGAGTGCTCTGGGCTCTG.

ChIPSeq

Each biological sample was generated from pooled pancreata isolated from 10–15 E14.5 CD1 embryos, or 3000–5000 pancreatic islets. The dissected tissues were cross-linked as described previously (Tuteja et al. 2008). After washing in PBS to remove excess formaldehyde and glycine, the fixed tissues were homogenized in 200 μ L of cold whole-cell lysis buffer (10 mM Tris-HCl at pH 8.0, 10 mM NaCl, 3 mM MgCl₂, 1% NP-40, 0.1% SDS, 0.5% deoxycholic acid) and protease inhibitors. After incubating on ice for 10 min, lysates were sonicated using a Diagenode Bioruptor (30-sec on/off pulses for 10 min, on high setting). Debris was removed by centrifugation at 13,000g for 10 min, and the supernatant was collected and snap frozen in liquid nitrogen. As input, 10 μ L of sonicated chromatin was incubated in PBS with 200 mM NaCl overnight at 65°C, treated with proteinase K and purified with the QIAquick PCR Purification Kit (Qiagen).

Immunoprecipitations were performed as previously described (Tuteja et al. 2008), except that the herring sperm DNA was excluded from the agarose bead-blocking step. For ChIPSeq experiments, the immunoprecipitated DNA was modified for sequencing following the manufacturer's protocol (Illumina). Briefly, DNAs were blunted with a combination of T4 DNA polymerase, Klenow polymerase, and T4 PNK, then a single 3'-end "A" base was added using Klenow exo (3'-to-5' exo minus). Adapters provided by Illumina were then ligated to the ends of the modified DNA before size selection of ~200-bp fragments via PAGE extraction. The isolated DNA samples were used as the template for amplification by 18 cycles of PCR. Amplified products were column purified with the QIAquick PCR Purification Kit (Qiagen) and assayed for quantity and quality with the Agilent 2100 Bioanalyzer (Agilent Technologies). Cluster generation and sequence alignment to the mouse genome (mm8) following pipeline processing were performed following Illumina's protocol. Only sequence tags uniquely mapping to the *Pdx1* locus were considered for this analysis.

Immunoprecipitated DNA was also used to confirm enrichment of target DNA fragments via qPCR. PCR reactions were assembled in triplicate with SYBR GreenER qPCR Supermix (Invitrogen) and run using the SYBR Green (with dissociation curve) program on the Mx3000 Multiplex Quantitative PCR System (Stratagene). The enrichment of target sequences in ChIP material was calculated relative to the myelin basic protein (MBP) locus as a reference for nonspecific binding, and normalized to their relative amplification in input DNA.

Acknowledgments

We thank Dr. Catherine Lee for critical reading the manuscript, Dr. Hong Fu for ES cell work, Sophia Hammani and Elizabeth

Helmbrecht for maintaining our mouse colony, Dr. Douglas Melton for kindly providing us with the *Pdx1*^{Cre} mice, and Dr. Christopher Wright for the Pdx1 and Ptf1a antibodies. We thank Alan Fox, Olga Smirnova, Geetu Tuteja, and Dr. Peter White for help with the ChIPSeq experiment. We are grateful to the Penn Morphology Core (P30DK50306) for tissue embedding and sectioning. This work was supported by NIDDK grants R01-DK055342 and P01-DK049210 to K.H.K. N.G. is supported by a JDRF fellowship (3-2007-521).

References

- Ahlgren, U., Pfaff, S.L., Jessell, T.M., Edlund, T., and Edlund, H. 1997. Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. *Nature* **385**: 257–260.
- Apelqvist, A., Li, H., Sommer, L., Beatus, P., Anderson, D.J., Honjo, T., Hrabe de Angelis, M., Lendahl, U., and Edlund, H. 1999. Notch signalling controls pancreatic cell differentiation. *Nature* **400**: 877–881.
- Behr, R., Brestelli, J., Fulmer, J.T., Miyawaki, N., Kleyman, T.R., and Kaestner, K.H. 2004. Mild nephrogenic diabetes insipidus caused by Foxa1 deficiency. *J. Biol. Chem.* **279**: 41936–41941.
- Ben-Shushan, E., Marshak, S., Shoshkes, M., Cerasi, E., and Meloul, D. 2001. A pancreatic β -cell-specific enhancer in the human PDX-1 gene is regulated by hepatocyte nuclear factor 3 β (HNF-3 β), HNF-1 α , and SPs transcription factors. *J. Biol. Chem.* **276**: 17533–17540.
- Boyer, D.F., Fujitani, Y., Gannon, M., Powers, A.C., Stein, R.W., and Wright, C.V. 2006. Complementation rescue of Pdx1 null phenotype demonstrates distinct roles of proximal and distal cis-regulatory sequences in pancreatic and duodenal expression. *Dev. Biol.* **298**: 616–631.
- Chen, Y., Pan, F.C., Brandes, N., Afelik, S., Solter, M., and Pieler, T. 2004. Retinoic acid signaling is essential for pancreas development and promotes endocrine at the expense of exocrine cell differentiation in *Xenopus*. *Dev. Biol.* **271**: 144–160.
- Ferri, A.L., Lin, W., Mavromatakis, Y.E., Wang, J.C., Sasaki, H., Whitsett, J.A., and Ang, S.L. 2007. Foxa1 and Foxa2 regulate multiple phases of midbrain dopaminergic neuron development in a dosage-dependent manner. *Development* **134**: 2761–2769.
- Friedman, J.R., Larris, B., Le, P.P., Peiris, T.H., Arsenlis, A., Schug, J., Tobias, J.W., Kaestner, K.H., and Greenbaum, L.E. 2004. Orthogonal analysis of C/EBP β targets in vivo during liver proliferation. *Proc. Natl. Acad. Sci.* **101**: 12986–12991.
- Fujitani, Y., Fujitani, S., Boyer, D.F., Gannon, M., Kawaguchi, Y., Ray, M., Shiota, M., Stein, R.W., Magnuson, M.A., and Wright, C.V. 2006. Targeted deletion of a cis-regulatory region reveals differential gene dosage requirements for Pdx1 in foregut organ differentiation and pancreas formation. *Genes & Dev.* **20**: 253–266.
- Gannon, M., Gamer, L.W., and Wright, C.V. 2001. Regulatory regions driving developmental and tissue-specific expression of the essential pancreatic gene *pdx1*. *Dev. Biol.* **238**: 185–201.
- Gao, N., Ishii, K., Mirosevich, J., Kuwajima, S., Oppenheimer, S.R., Roberts, R.L., Jiang, M., Yu, X., Shappell, S.B., Caprioli, R.M., et al. 2005. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. *Development* **132**: 3431–3443.
- Gao, N., White, P., Doliba, N., Golson, M.L., Matschinsky, F.M., and Kaestner, K.H. 2007. Foxa2 controls vesicle docking and insulin secretion in mature β cells. *Cell Metab.* **6**: 267–279.

- Gerrish, K., Gannon, M., Shih, D., Henderson, E., Stoffel, M., Wright, C.V., and Stein, R. 2000. Pancreatic β cell-specific transcription of the *pdx-1* gene. The role of conserved upstream control regions and their hepatic nuclear factor 3 β sites. *J. Biol. Chem.* **275**: 3485–3492.
- Gerrish, K., Cissell, M.A., and Stein, R. 2001. The role of hepatic nuclear factor 1 α and PDX-1 in transcriptional regulation of the *pdx-1* gene. *J. Biol. Chem.* **276**: 47775–47784.
- Gerrish, K., Van Velkinburgh, J.C., and Stein, R. 2004. Conserved transcriptional regulatory domains of the *pdx-1* gene. *Mol. Endocrinol.* **18**: 533–548.
- Gradwohl, G., Dierich, A., LeMeur, M., and Guillemot, F. 2000. *neurogenin3* is required for the development of the four endocrine cell lineages of the pancreas. *Proc. Natl. Acad. Sci.* **97**: 1607–1611.
- Gu, G., Dubauskaite, J., and Melton, D.A. 2002. Direct evidence for the pancreatic lineage: NGN3⁺ cells are islet progenitors and are distinct from duct progenitors. *Development* **129**: 2447–2457.
- Gu, G., Brown, J.R., and Melton, D.A. 2003. Direct lineage tracing reveals the ontogeny of pancreatic cell fates during mouse embryogenesis. *Mech. Dev.* **120**: 35–43.
- Guz, Y., Montminy, M.R., Stein, R., Leonard, J., Gamer, L.W., Wright, C.V., and Teitelman, G. 1995. Expression of murine STF-1, a putative insulin gene transcription factor, in β cells of pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during ontogeny. *Development* **121**: 11–18.
- Habener, J.F., Kemp, D.M., and Thomas, M.K. 2005. Minireview: Transcriptional regulation in pancreatic development. *Endocrinology* **146**: 1025–1034.
- Heiser, P.W., Lau, J., Taketo, M.M., Herrera, P.L., and Hebrok, M. 2006. Stabilization of β -catenin impacts pancreas growth. *Development* **133**: 2023–2032.
- Jonsson, J., Carlsson, L., Edlund, T., and Edlund, H. 1994. Insulin-promoter-factor 1 is required for pancreas development in mice. *Nature* **371**: 606–609.
- Jorgensen, M.C., Ahnfelt-Ronne, J., Hald, J., Madsen, O.D., Serup, P., and Hecksher-Sorensen, J. 2007. An illustrated review of early pancreas development in the mouse. *Endocr. Rev.* **28**: 685–705.
- Kaestner, K.H., Hiemisch, H., Luckow, B., and Schutz, G. 1994. The HNF-3 gene family of transcription factors in mice: Gene structure, cDNA sequence, and mRNA distribution. *Genomics* **20**: 377–385.
- Kaestner, K.H., Katz, J., Liu, Y., Drucker, D.J., and Schutz, G. 1999. Inactivation of the winged helix transcription factor HNF3 α affects glucose homeostasis and islet glucagon gene expression in vivo. *Genes & Dev.* **13**: 495–504.
- Kawaguchi, Y., Cooper, B., Gannon, M., Ray, M., MacDonald, R.J., and Wright, C.V. 2002. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. *Nat. Genet.* **32**: 128–134.
- Krapp, A., Knofler, M., Ledermann, B., Burki, K., Berney, C., Zoerkler, N., Hagenbuchle, O., and Wellauer, P.K. 1998. The bHLH protein PTF1-p48 is essential for the formation of the exocrine pancreas and the correct spatial organization of the endocrine pancreas. *Genes & Dev.* **12**: 3752–3763.
- Lai, E., Prezioso, V.R., Tao, W.F., Chen, W.S., and Darnell Jr., J.E. 1991. Hepatocyte nuclear factor 3 α belongs to a gene family in mammals that is homologous to the *Drosophila* homeotic gene fork head. *Genes & Dev.* **5**: 416–427.
- Lammert, E., Cleaver, O., and Melton, D. 2001. Induction of pancreatic differentiation by signals from blood vessels. *Science* **294**: 564–567.
- Lammert, E., Cleaver, O., and Melton, D. 2003. Role of endothelial cells in early pancreas and liver development. *Mech. Dev.* **120**: 59–64.
- Lee, C.S., Sund, N.J., Vatamaniuk, M.Z., Matschinsky, F.M., Stoffers, D.A., and Kaestner, K.H. 2002. Foxa2 controls Pdx1 gene expression in pancreatic β -cells in vivo. *Diabetes* **51**: 2546–2551.
- Lee, C.S., Sund, N.J., Behr, R., Herrera, P.L., and Kaestner, K.H. 2005. Foxa2 is required for the differentiation of pancreatic α -cells. *Dev. Biol.* **278**: 484–495.
- Martin, M., Gallego-Llomas, J., Ribes, V., Keding, M., Niederreither, K., Chambon, P., Dolle, P., and Gradwohl, G. 2005. Dorsal pancreas agenesis in retinoic acid-deficient *Raldh2* mutant mice. *Dev. Biol.* **284**: 399–411.
- Molotkov, A., Molotkova, N., and Duester, G. 2005. Retinoic acid generated by *Raldh2* in mesoderm is required for mouse dorsal endodermal pancreas development. *Dev. Dyn.* **232**: 950–957.
- Monaghan, A.P., Kaestner, K.H., Grau, E., and Schutz, G. 1993. Postimplantation expression patterns indicate a role for the mouse forkhead/HNF-3 α , β and γ genes in determination of the definitive endoderm, chordamesoderm and neuroectoderm. *Development* **119**: 567–578.
- Moriya, N., Komazaki, S., Takahashi, S., Yokota, C., and Asashima, M. 2000. In vitro pancreas formation from *Xenopus* ectoderm treated with activin and retinoic acid. *Dev. Growth Differ.* **42**: 593–602.
- Murtaugh, L.C. 2007. Pancreas and β -cell development: From the actual to the possible. *Development* **134**: 427–438.
- Offield, M.F., Jetton, T.L., Labosky, P.A., Ray, M., Stein, R.W., Magnuson, M.A., Hogan, B.L., and Wright, C.V. 1996. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. *Development* **122**: 983–995.
- Rodriguez, C.I., Buchholz, F., Galloway, J., Sequerra, R., Kasper, J., Ayala, R., Stewart, A.F., and Dymecki, S.M. 2000. High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. *Nat. Genet.* **25**: 139–140.
- Samaras, S.E., Cissell, M.A., Gerrish, K., Wright, C.V., Gannon, M., and Stein, R. 2002. Conserved sequences in a tissue-specific regulatory region of the *pdx-1* gene mediate transcription in Pancreatic β cells: Role for hepatocyte nuclear factor 3 β and Pax6. *Mol. Cell. Biol.* **22**: 4702–4713.
- Samaras, S.E., Zhao, L., Means, A., Henderson, E., Matsuoka, T.A., and Stein, R. 2003. The islet β cell-enriched RIPE3b1/Maf transcription factor regulates *pdx-1* expression. *J. Biol. Chem.* **278**: 12263–12270.
- Sander, M., Neubuser, A., Kalamaras, J., Ee, H.C., Martin, G.R., and German, M.S. 1997. Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development. *Genes & Dev.* **11**: 1662–1673.
- Sander, M., Sussel, L., Connors, J., Scheel, D., Kalamaras, J., Dela Cruz, F., Schwitzgebel, V., Hayes-Jordan, A., and German, M. 2000. Homeobox gene *Nkx6.1* lies downstream of *Nkx2.2* in the major pathway of β -cell formation in the pancreas. *Development* **127**: 5533–5540.
- Schwitzgebel, V.M., Scheel, D.W., Connors, J.R., Kalamaras, J., Lee, J.E., Anderson, D.J., Sussel, L., Johnson, J.D., and German, M.S. 2000. Expression of *neurogenin3* reveals an islet cell precursor population in the pancreas. *Development* **127**: 3533–3542.
- Sharma, S., Jhala, U.S., Johnson, T., Ferreri, K., Leonard, J., and Montminy, M. 1997. Hormonal regulation of an islet-specific enhancer in the pancreatic homeobox gene STF-1. *Mol. Cell. Biol.* **17**: 2598–2604.
- Shih, D.Q., Navas, M.A., Kuwajima, S., Duncan, S.A., and Stoffel, M. 1999. Impaired glucose homeostasis and neonatal mortality in hepatocyte nuclear factor 3 α -deficient mice.

Gao et al.

- Proc. Natl. Acad. Sci.* **96**: 10152–10157.
- Soriano, P. 1999. Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat. Genet.* **21**: 70–71.
- Stafford, D. and Prince, V.E. 2002. Retinoic acid signaling is required for a critical early step in zebrafish pancreatic development. *Curr. Biol.* **12**: 1215–1220.
- Stoffers, D.A., Zinkin, N.T., Stanojevic, V., Clarke, W.L., and Habener, J.F. 1997. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. *Nat. Genet.* **15**: 106–110.
- Sund, N.J., Ang, S.L., Sackett, S.D., Shen, W., Daigle, N., Magnuson, M.A., and Kaestner, K.H. 2000. Hepatocyte nuclear factor 3 β (Foxa2) is dispensable for maintaining the differentiated state of the adult hepatocyte. *Mol. Cell. Biol.* **20**: 5175–5183.
- Sund, N.J., Vatamaniuk, M.Z., Casey, M., Ang, S.L., Magnuson, M.A., Stoffers, D.A., Matschinsky, F.M., and Kaestner, K.H. 2001. Tissue-specific deletion of Foxa2 in pancreatic β cells results in hyperinsulinemic hypoglycemia. *Genes & Dev.* **15**: 1706–1715.
- Sussel, L., Kalamaras, J., Hartigan-O'Connor, D.J., Meneses, J.J., Pedersen, R.A., Rubenstein, J.L., and German, M.S. 1998. Mice lacking the homeodomain transcription factor Nkx2.2 have diabetes due to arrested differentiation of pancreatic β cells. *Development* **125**: 2213–2221.
- Tuteja, G., Jensen, S.T., White, P., and Kaestner, K.H. 2008. Cis-regulatory modules in the mammalian liver: Composition depends on strength of Foxa2 consensus site. *Nucleic Acids Res.* **36**: 4149–4167.
- Vanhoose, A.M., Samaras, S., Artner, I., Henderson, E., Hang, Y., and Stein, R. 2008. MafA and MafB regulate Pdx1 transcription through the Area II control region in pancreatic β cells. *J. Biol. Chem.* **283**: 22612–22619.
- Vatamaniuk, M.Z., Gupta, R.K., Lantz, K.A., Doliba, N.M., Matschinsky, F.M., and Kaestner, K.H. 2006. Foxa1-deficient mice exhibit impaired insulin secretion due to uncoupled oxidative phosphorylation. *Diabetes* **55**: 2730–2736.
- Wan, H., Dingle, S., Xu, Y., Besnard, V., Kaestner, K.H., Ang, S.L., Wert, S., Stahlman, M.T., and Whitsett, J.A. 2005. Compensatory roles of Foxa1 and Foxa2 during lung morphogenesis. *J. Biol. Chem.* **280**: 13809–13816.
- Wang, J., Elghazi, L., Parker, S.E., Kizilocak, H., Asano, M., Sussel, L., and Sosa-Pineda, B. 2004. The concerted activities of Pax4 and Nkx2.2 are essential to initiate pancreatic β -cell differentiation. *Dev. Biol.* **266**: 178–189.
- Wiebe, P.O., Kormish, J.D., Roper, V.T., Fujitani, Y., Alston, N.I., Zaret, K.S., Wright, C.V., Stein, R.W., and Gannon, M. 2007. Ptf1a binds to and activates area III, a highly conserved region of the Pdx1 promoter that mediates early pancreas-wide Pdx1 expression. *Mol. Cell. Biol.* **27**: 4093–4104.
- Wu, K.L., Gannon, M., Peshavaria, M., Offield, M.F., Henderson, E., Ray, M., Marks, A., Gamer, L.W., Wright, C.V., and Stein, R. 1997. Hepatocyte nuclear factor 3 β is involved in pancreatic β -cell-specific transcription of the pdx-1 gene. *Mol. Cell. Biol.* **17**: 6002–6013.
- Zhou, Q., Law, A.C., Rajagopal, J., Anderson, W.J., Gray, P.A., and Melton, D.A. 2007. A multipotent progenitor domain guides pancreatic organogenesis. *Dev. Cell* **13**: 103–114.

Dynamic regulation of *Pdx1* enhancers by Foxa1 and Foxa2 is essential for pancreas development

Nan Gao, John LeLay, Marko Z. Vatamaniuk, et al.

Genes Dev. 2008, **22**:

Access the most recent version at doi:[10.1101/gad.1752608](https://doi.org/10.1101/gad.1752608)

Supplemental Material

<http://genesdev.cshlp.org/content/suppl/2008/12/16/22.24.3435.DC1>

References

This article cites 60 articles, 33 of which can be accessed free at:
<http://genesdev.cshlp.org/content/22/24/3435.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).